Relacorilant + Enzalutamide
Prostate cancer
Phase 2Active (Investigator-sponsored)
Key Facts
Indication
Prostate cancer
Phase
Phase 2
Status
Active (Investigator-sponsored)
Company
About Corcept Therapeutics
Corcept Therapeutics is a leader in cortisol modulation science, with over 25 years of research and the discovery of more than 1,000 proprietary selective cortisol modulators. The company's mission is to unlock the potential of cortisol modulation to revolutionize the treatment of serious diseases, supported by a robust pipeline with more than 30 ongoing studies across endocrinology, oncology, metabolism, and neurology. With its first FDA-approved product generating revenue and multiple late-stage clinical programs, Corcept is positioned to expand its impact significantly in the coming years.
View full company profileTherapeutic Areas
Other Prostate cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Erleada (apalutamide) | Johnson & Johnson | Approved |
| Nubeqa (darolutamide) | Bayer | Approved |
| Xtandi (enzalutamide) | Astellas Pharma | Approved |
| Proxalutamide (HS-10370) | Hansoh Pharma | Phase 3 |
| Darolutamide (Nubeqa) | Orion Corporation | Approved |
| NBTXR3 | Nanobiotix | Phase 1/2 |
| Praluzatamab ravtansine (CX-2009) | CytomX Therapeutics | Phase 1/2 |
| Bavdegalutamide (ARV-110) | Arvinas | Phase 2 |
| ARV-766 | Arvinas | Phase 2 |
| Alpha DaRT | Alpha Tau Medical | Phase 1/2 |
| Prognostic Genomic Tests | Eurobio Scientific | Commercial |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |